Welcome
prof. dr hab. n. med. Krzysztof Narkiewicz,
prof. Michel Burnier
5 min
08:35 – 09:50
Session 1. From biomarkers to clinical decisions — what really changes practice
Chairs:
prof. dr hab. n. med. Andrzej Januszewicz,
prof. Alexandre Persu
75 min
08:35 - 08:50
Why do we need biomarkers — what do they add beyond conventional risk factors?
Carmine Zoccali
08:50 - 09:05
Different biomarkers, different questions
Francesca Mallamaci
09:05 - 09:20
From association to clinical utility — how should a new biomarker be validated?
prof. Christian Delles
09:20 - 09:35
When should a biomarker change treatment?
09:35 - 09:50
Discussion
09:50 – 10:10
Coffee break
20 min
10:10 – 12:10
Session 2. Hypertension in 2027: promises and disappointments in biomarkers, risk stratification and treatment targets
120 min
10:10 - 10:25
Homocysteine and B vitamins — old story, new evidence?
10:25 - 10:40
Inflammation and vascular dysfunction in hypertension — does hsCRP add value?
Daniela Carnevale
10:40 - 10:55
hs-Troponin and NT-proBNP — ready for risk stratification in hypertension?
prof. Gianfranco Parati
10:55 - 11:10
MicroRNAs — still promising or a missed opportunity?
11:10 - 11:25
Renin and aldosterone — can we use them to guide treatment?
11:25 - 11:40
Sympathetic activation — can we identify and treat the phenotype?
Stefano Masi
11:40 - 12:10
Discussion
12:30 – 14:00
Lunch
90 min
14:00 – 16:00
Session 3. Biomarkers in CKD — from progression to nephroprotective treatment
Chairs:
Liffert Vogt,
prof. Michel Burnier
120 min
14:00 - 14:15
New blood and urine biomarkers — do they improve risk prediction?
14:15 - 14:30
Tubular biomarkers — can they improve assessment of kidney injury and progression?
. Marius Miglinas
14:30 - 14:45
Albuminuria and eGFR slope — still the benchmarks?
Alberto Ortiz
14:45 - 15:00
Afamin — promising biomarker or another association?
15:00 - 15:15
pre-CKD (hrCKD) — new clinical entity in nephrology defined by biomarkers
prof. dr hab. n. med. Marcin Adamczak
15:15 - 15:30
From risk prediction to treatment selection — can biomarkers guide nephroprotection?
prof. dr hab. n. med. Andrzej Więcek
15:30 - 16:00
Discussion
16:00 – 16:20
Coffee break
20 min
16:25 – 17:35
Session 4. Heart Failure: from biomarkers to precision therapy and proactive care
Chairs:
prof. Gianfranco Parati,
Piotr Ponikowski
70 min
16:25 - 16:32
From molecular signatures to treatable endotypes: can multi-omics guide heart failure therapy?
16:32 - 16:44
Precision decongestion: urine sodium and beyond
dr hab. n. med., prof. UMW Jan Biegus
16:44 - 16:56
From blood tests to biosensors: towards real-time monitoring in heart failure
16:56 - 17:08
From multi-modal monitoring to supported self-management: can we prevent worsening heart failure?
17:08 - 17:20
Biomarker-guided precision medicine in heart failure: promise or clinical reality?
prof. dr hab. n. med. Ewa Jankowska
17:20 - 17:35
Panel discussion: from biomarker signals to clinical decisions — what is ready for practice?
Gdańsk, Poland | 22–24 April 2027
09:00 – 10:15
Session 5. Beyond blood biomarkers — digital phenotyping and imaging
75 min
09:00 - 09:15
Digital biomarkers in peripheral artery disease — ready for clinical use?
09:15 - 09:30
Renal MRI biomarkers — from tissue characterization to clinical decisions
09:30 - 09:45
Imaging biomarkers for Kidney Function and Disease: MRI and beyond
dr Anna Caroli
09:45 - 10:00
Cardiac CT and MRI biomarkers — what changes clinical management?
10:00 - 10:15
Discussion
10:15 – 10:35
Coffee break
20 min
10:35 – 11:50
Session 6. The future of biomarkers — what comes next?
Chairs:
dr Jan Danser,
prof. dr hab. n. med. Krzysztof Narkiewicz
75 min
10:35 - 10:50
From biomarkers to physiology — what can we learn from the kidney?
10:50 - 11:05
Will genetic biomarkers change clinical practice?
Olle Melander
11:05 - 11:20
Risk assessment in hypertension — where will biomarkers fit?
11:20 - 11:35
From cardiovascular risk prediction to treatment — which biomarkers will really matter in 2030?
11:35 - 11:50
Discussion
11:50 – 12:30
Discussion and closure of the meeting
Chairs:
prof. dr hab. n. med. Krzysztof Narkiewicz,
prof. Michel Burnier
Witryna konferencji używa cookies. Są to niewielkie pliki tekstowe wysyłane przez serwer www i przechowywane przez oprogramowanie komputera przeglądarki. Kiedy przeglądarka ponownie połączy się ze stroną, witryna rozpoznaje rodzaj urządzenia, z którego łączy się użytkownik.
Parametry pozwalają na odczytanie informacji w nich zawartych jedynie serwerowi, który je utworzył. Cookies ułatwiają więc korzystanie z wcześniej odwiedzonych witryn.